With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Like Bio-Hermes-001, the Bio-Hermes-002 study is setting a standard for improving participation from people who are traditionally underrepresented in Alzheimer's clinical research, with an ...

Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...

Emil Kraepelin formulated the initial nosology of Alzheimer's disease in the first decade of the 20th century. Nowadays, clinical and pathological presentations (including those associated with ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.